Mobilisation of haemopoietic progenitors in CML: A second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests

Bone Marrow Transplantation

Volumn 25, Issue 11, 2000, Pages 1147-1155

  Janssen, J J W M ^a   Van Rijn, R S ^b   Van Der Holt, B ^e   Schuurhuis, G J ^a   Vellenga, E ^c   Verhoef, G E G ^d   Ossenkoppele, G J ^a   Van Den Berg, E ^c   Hagemeijer, A ^d   Slater R ^e   Nieuwint, A W M ^a   Cornelissen, J J ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e NONE

Author keywords

Autologous stem cell transplantation; CML; Intensive chemotherapy

Indexed keywords

ALPHA INTERFERON; AMSACRINE; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MUCOSA INFLAMMATION; PHILADELPHIA 1 CHROMOSOME; PNEUMONIA; PRIORITY JOURNAL;

EID: 0034043557     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702420     Document Type: Article

References (49)

1. Fialkow PJ, Jacobson RJ, Singer JW et al. Philadelphia chromosome (Phl)-negative chronic myelogenous leukemia (CML): a clonal disease with origin in a multipotent stem cell. Blood 1980; 56: 70-73.
2. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
3. O'Brien SG. Autografting in chronic myeloid leukaemia. Baillières Clin Haematol 1997; 10: 369-388.
4. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345: 1392-1397.
5. Hehlmann R, Heimpel H. Hasford J et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84: 4064-4077.
6. Tura S, Baccarani M, Zuffa E et al. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. New Engl J Med 1994; 330: 820-825.
7. Hoyle C, Gray R, Goldman J. Autografting for patients with CML in chronic phase: an update. Hammersmith BMT Team LRF Centre for Adult Leukaemia. Br J Haematol 1994; 86: 76-81.
8. Reiffers J, Goldman J, Meloni G et al. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant 1994; 14: 407-410.
9. Carella AM, Podesta M, Frassoni F et al. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 1993; 12: 267-271.
10. Carella AM, Simonsson B, Link H et al. Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha. Br J Haematol 1998; 101: 111-118.
11. Waller CF, Heinzinger M, Rosenstiel A et al. Mobilization and transplantation of Philadelphia chromosome-negative peripheral blood progenitor cells in patients with CML. Br J Haematol 1998; 103: 227-234.
12. Carella AM, Lerma E, Celesti L et al. Effective mobilization of Philadelphia-chromosome-negative cells in chronic myelogenous leukaemia patients using a less intensive regimen. Br J Haematol 1998; 100: 445-448.
13. Aulitzky WE, Neubauer A, Kolbe K et al. Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3. Bone Marrow Transplant 1996; 17 (Suppl 3): S67-S69.
14. Boqué C, Petit J, Sarra J et al. Mobilization of peripheral stem cells with intensive chemotherapy (ICE regimen) and G-CSF in chronic myeloid leukemia. Bone Marrow Transplant 1996; 18: 879-884.
15. Chalmers EA, Franklin IM, Kelsey SM et al. Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells. Br J Haematol 1997; 96: 627-634.
16. Fischer T, Neubauer A, Mohm J et al. Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied. Ann Hematol 1998; 77: 21-26.
17. Hughes TP, Grigg A, Szer J et al. Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronicphase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control. Br J Haematol 1997; 96: 635-640.
18. Johnson RJ, Owen RG, Child JA et al. Mobilization of Philadelphia-negative peripheral blood mononuclear cells in chronic myeloid leukaemia using hydroxyurea and G-CSF (filgrastim). Br J Haematol 1996; 93: 863-868.
19. Reiffers J, Taylor K, Gluckman E et al. Collection of Ph-negative progenitor cells with granulocyte-colony stimulating factor in patients with chronic myeloid leukaemia who respond to recombinant alpha-interferon. Br J Haematol 1998; 102: 639-646.
20. Talpaz M, Kantarjian H, Liang J et al. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood 1995; 85: 3257-3263.
21. Thijsen SFT, Schuurhuis GJ, van Oostveen JW et al. Molecular analysis of hematopoietic colonies derived from chronic myeloid leukemia patients: interphase fluorescence in situ hybridisation compared with RT-PCR. Leukemia 1996; 1: 1-2.
22. Coulombel L, Kalousek DK, Eaves CJ et al. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. New Engl J Med 1983; 308: 1493-1498.
23. Vellenga E, van Putten W, Boogaerts MA et al. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? Bone Marrow Transplant 1999; 23: 1279-1282.
24. Amarante-Mendes GP, Jascur T, Nishioka WK et al. Bcr-abl-mediated resistance to apoptosis is independent of PI 3-kinase activity. Cell Death Diff 1997; 4: 548-554.
25. Amarante-Mendes GP, McGahon AJ, Nishioka WK et al. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up-regulation of Bcl-xL. Oncogene 1998; 16: 1383-1390.
26. McGahon AJ, Brown DG, Martin SJ et al. Downregulation of bcr-abl in K562 cells restores susceptibility to apoptosis -characterization of the apoptotic death. Cell Death Diff 1997; 4: 95-104.
27. Bedi A, Zehnbauer BA, Barber JP et al. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83: 2038-2044.
28. Fernandes RS, Gorman AM, McGahon A et al. The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia (review). Leukemia 1996; 10 (Suppl 2): S17-S21.
29. McGahon A, Bissonnette R. Schmitt M et al. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179-1187.
30. McGahon AJ, Nishioka WK, Martin SJ et al. Regulation of the Fas apoptotic cell death pathway by abl. J Biol Chem 1995; 270: 22625-22631.
31. Bedi A, Barber JP, Bedi GC et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995; 86: 1148-1158.
32. Carella AM, Cunningham I, Lerma E et al. Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia. J Clin Oncol 1997; 15: 1575-1582.
33. Carella AM, Lerma E, Corsetti MT et al. Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999; 93: 1534-1539.
34. Sureda A, Petit J, Brunet S et al. Mini-lCE regimen as mobilization therapy for chronic myelogenous leukaemia patients at diagnosis. Bone Marrow Transplant 1999; 24: 1285-1290.
35. Simonsson B, Öberg G, Bjoreman M et al. Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group. Bone Marrow Transplant 1996; 17 (Suppl 3): S63-S64.
36. Simonsson B, Öberg G. Linder O et al. Intensive treatment in order to minimize the Ph-positive clone in CML. Blood 1997; 90 (Suppl 1): 392a (Abstr.).
37. McGlave PB, De Fabritiis P, Deisseroth A et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343: 1486-1488.
38. Reiffers J, Mahon FX, Boiron JM et al. Autografting in chronic myeloid leukemia - an overview. Leukemia 1996: 10: 385-388.
39. Reiffers J, Trouette R. Marit G et al. Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases. Br J Haematol 1991: 77: 339-345.
40. Haines ME, Goldman JM, Worsley AM et al. Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: probable prolongation of survival for some patients. Br J Haematol 1984; 58: 711-721.
41. Druker BJ, Talpaz M, Resta D et al. Clinical efficacy and safety of an abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia. Blood 1999; 94 (Suppl 1): 368a (Abstr.).
42. Archimbaud E, Michallet M, Philip I et al. Granulocyte colony-stimulating factor given in addition to interferon-alpha to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukaemia. Br J Haematol 1997; 99: 678-684.
43. Fischer T, Neubauer A, Mohm J et al. Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML. Bone Marrow Transplant 1998; 21: 1029-1036.
44. Kantarjian HM, Talpaz M, Hester J et al. Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy. J Clin Oncol 1995; 13: 553-559.
45. Lennard AL, Storey N, Dickinson AM et al. Collection of Philadelphia-negative peripheral blood progenitor cells in unselected patients with chronic granulocytic leukaemia. Leukemia 1998; 12: 746-752.
46. McGlave P, Bhatia R, Verfaillie C. Cyclophosphamide/GM-CSF priming in autotransplant therapy for CML. Bone Marrow Transplant 1996; 17 (Suppl 3): S65-S66.
47. Morton J, Mollee P, Taylor K et al. Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor. Leukemia Res 1999; 23: 177-183.
48. Pratt G. Johnson RJ. Rawstron AC et al. Autologous stem cell transplantation in chronic myeloid leukaemia using Philadelphia chromosome negative blood progenitors mobilised with hydroxyurea and G-CSF. Bone Marrow Transplant 1998; 21: 455-460.
49. Verfaillie CM, Bhatia R, Steinbuch M et al. Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells. Blood 1998; 92: 1820-1831.